The Opportunity

The immune system is central to human disease and health

When it functions correctly, it fights off infections;
When it is overactive, it can lead to autoimmune disease;
When it becomes dysfunctional, cancer can take hold.

If we can characterize the immune system at a deep level of granularity and consistency, we can unlock insights that will dramatically enhance our understanding of health, disease and therapeutic development. For cancer and well beyond.

Immunai’s immune profiling platform

Immunai combines comprehensive, multi-omic single cell genomics with cutting edge machine learning algorithms to enable high resolution profiling of the immune system, at industrial scale, with rapid turnaround.

Immunai’s end to end platform is generating the world’s largest knowledge base of high granularity immunological data.

Our goal is to decode the immune system, and use this knowledge to unlock biological insights that:

Accelerate

clinical trials and avoid costly failures

Improve efficacy

of immunotherapies and combinations

Power

the next generation of therapeutics

Immunai’s Advantage

Better Data

Better Analysis

Better Insights

Better Data

Multi-omic single cell biological assays
consistently executed protocols for single cell immunology

Functional genomic screens
refined with machine learning algorithms

Advanced data integration
and bioinformatics infrastructure

Dependable, consistently curated single cell data
from both clinical trials and public literature

Better Data

Better Analysis

Better Insights

Better Analysis

Machine Learning
incorporated as core architecture

Differentiate
between cell subtypes and substates at hypergranular resolution

Identify rare cell types
and longitudinally track clonal expansion and phenotypic change

Batch
harmonization enabling analysis at scale

Better Data

Better Analysis

Better Insights

Characterize immune mechanisms of response and resistance

Data-driven design of synergistic immunotherapy combinations

Measure immune response as a surrogate endpoint for clinical response

Discover predictive markers of response or resistance

Measure heterogeneity in CAR T cell therapy product

Identify rare cell subtypes or sub-states that correlate with outsized clinical effect

Better Data

Multi-omic single cell biological assays:
consistently executed protocols for single cell immunology

Functional genomic screens
refined with machine learning algorithms

Advanced data integration
and bioinformatics infrastructure

Dependable, consistent single cell data
at clinical trial scale - 100s to 1000s of samples

Better Analysis

Machine Learning
incorporated as core architecture

Differentiate
between cell subtypes and substates at hypergranular resolution

Identify rare cell types
and longitudinally track clonal expansion and phenotypic change

Batch
harmonization enabling analysis at scale

Better Insights

Characterize immune mechanisms of response and resistance

Data-driven design of synergistic immunotherapy combinations

Measure immune response as a surrogate endpoint for clinical response

Discover predictive markers of response or resistance

Measure heterogeneity in CAR T cell therapy product

Identify rare cell subtypes or sub-states that correlate with outsized clinical effect

Solutions

Our platform is used to advance research and development in checkpoint blockade, cancer cell therapy, and cancer vaccines.

We partner with academic research institutions, biopharmaceutical players, and biotechs to explore new indications and additional high value applications of our technology and data.

The immune system is central to human disease and health

Immunai’s immune profiling platform

Immunai’s end to end platform is generating the world’s largest knowledge base of high granularity immunological data.

Better Data

Better Analysis

Better Insights

Better Data

Better Analysis

Better Insights

Our platform is used to advance research and development in checkpoint blockade, cancer cell therapy, and cancer vaccines.

Interested? Connect with us to learn more